{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:00:15Z","timestamp":1681887615787},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"1068","license":[{"start":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T00:00:00Z","timestamp":1410912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Many paediatric rheumatic diseases result from the abnormal activation or control of the immune system. Biologic drugs, which are synthesised within a biological system, have been designed to target specific molecules involved in cytokine signalling or cell\u2013cell interactions. The past 15\u2005years have seen a revolution in the range of effective treatments for rheumatic diseases, particularly juvenile idiopathic arthritis (JIA). As a result, the target of inactive disease and minimal long-term disease-associated damage is increasingly becoming achievable. In this article we review evidence from recent trials of the use of biologic drugs in the treatment of systemic JIA, juvenile dermatomyositis and juvenile systemic lupus erythematosus. We also highlight novel agents currently undergoing investigation which may broaden our therapeutic armamentarium over the coming decade. Key to these developments are well-designed multicentre controlled clinical trials and long-term safety monitoring as part of international drug registries.<\/jats:p>","DOI":"10.1136\/postgradmedj-2013-304396rep","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T16:00:08Z","timestamp":1410969608000},"page":"590-596","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Republished: New age of biological therapies in paediatric rheumatology"],"prefix":"10.1093","volume":"90","author":[{"given":"Ethan S","family":"Sen","sequence":"first","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children , Bristol , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A V","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children , Bristol , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,9,17]]},"reference":[{"key":"2023041906092671500_R1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"2023041906092671500_R2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4161\/self.1.4.13560","article-title":"Immunopathogenesis of inflammatory bowel disease","volume":"1","author":"Matricon","year":"2010","journal-title":"Self Nonself"},{"key":"2023041906092671500_R3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/adc.2009.170860","article-title":"New advances in the management of juvenile idiopathic arthritis\u20142: the era of biologicals","volume":"94","author":"Beresford","year":"2009","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"2023041906092671500_R4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"2023041906092671500_R5","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"2023041906092671500_R7","article-title":"A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy"},{"key":"2023041906092671500_R8","article-title":"A multicenter, open-label study to assess the pharmacokinetics, safety and efficacy of certolizumab pegol in children and adolescents with moderately to severely active polyarticular-course juvenile idiopathic arthritis (JIA)"},{"key":"2023041906092671500_R9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023041906092671500_R10","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"2023041906092671500_R11","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"2023041906092671500_R13","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2023041906092671500_R14","first-page":"S682","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial","volume":"64","author":"Brunner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"2023041906092671500_R16","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2023041906092671500_R18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10067-010-1630-0","article-title":"B cell depletion for autoimmune diseases in paediatric patients","volume":"30","author":"Jansson","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2023041906092671500_R19","article-title":"A multi-center, randomized, placebo-controlled trial to evaluate the safety, efficacy, and pharmacokinetics of belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric patients with systemic lupus erythematosus"},{"key":"2023041906092671500_R20","article-title":"An open-label multiple dose study to evaluate the pharmacokinetics, safety and tolerability of CP-690,550 in pediatric patients from 2 to less than 18 years of age with juvenile idiopathic arthritis (JIA)"},{"key":"2023041906092671500_R21","article-title":"A long-term, open-label follow-up study of CP-690,550 for treatment of juvenile idiopathic arthritis (JIA)"},{"key":"2023041906092671500_R22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2011.145","article-title":"Safety of biologic therapy in rheumatoid arthritis","volume":"7","author":"Woodrick","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2023041906092671500_R23","doi-asserted-by":"crossref","first-page":"939847","DOI":"10.1155\/2013\/939847","article-title":"Biological treatments: new weapons in the management of monogenic autoinflammatory disorders","volume":"2013","author":"Vitale","year":"2013","journal-title":"Mediators Inflamm"},{"key":"2023041906092671500_R24","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"2023041906092671500_R25","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2023041906092671500_R26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11882-013-0351-2","article-title":"Update on the treatment of juvenile idiopathic arthritis","volume":"13","author":"Harris","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"2023041906092671500_R27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1517\/14656566.2013.783569","article-title":"Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives","volume":"14","author":"Wahezi","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"2023041906092671500_R28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14712598.2013.735657","article-title":"Update on biologicals for treatment of juvenile idiopathic arthritis","volume":"13","author":"Horneff","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"2023041906092671500_R29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00431-010-1238-z","article-title":"Biologics in children\u2019s autoimmune disorders: efficacy and safety","volume":"170","author":"Breda","year":"2011","journal-title":"Eur J Pediatr"},{"key":"2023041906092671500_R30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/rheumatology\/keh710","article-title":"Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis","volume":"44","author":"Ramanan","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2023041906092671500_R31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/MOP.0b013e32834cba24","article-title":"Update on the pathogenesis and treatment of systemic idiopathic arthritis","volume":"23","author":"Sikora","year":"2011","journal-title":"Curr Opin Pediatr"},{"key":"2023041906092671500_R32","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"2023041906092671500_R33","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.22644","article-title":"Specific gene expression profiles in systemic juvenile idiopathic arthritis","volume":"56","author":"Ogilvie","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients","volume":"50","author":"Southwood","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2023041906092671500_R35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R36","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00296-011-2249-4","article-title":"Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)","volume":"32","author":"Hedrich","year":"2012","journal-title":"Rheumatol Int"},{"key":"2023041906092671500_R37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2012-202310","article-title":"Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan","volume":"72","author":"Yokota","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023041906092671500_R38","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","article-title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis","volume":"47","author":"Riley","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2023041906092671500_R40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2023041906092671500_R41","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023041906092671500_R42","article-title":"Pilot study of etanercept in patients with refractory juvenile dermatomyositis","author":"Rouster-Stevens","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023041906092671500_R43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R44","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/BOR.0b013e328363e868","article-title":"An update on childhood-onset systemic lupus erythematosus","volume":"25","author":"Barsalou","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"2023041906092671500_R45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/adc.2007.126276","article-title":"B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus","volume":"93","author":"Podolskaya","year":"2008","journal-title":"Arch Dis Child"},{"key":"2023041906092671500_R46","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00467-006-0024-7","article-title":"Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus","volume":"21","author":"Marks","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"2023041906092671500_R47","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"(Suppl 1)","key":"2023041906092671500_R49","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","article-title":"B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2023041906092671500_R50","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023041906092671500_R51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.berh.2013.07.006","article-title":"Biologics in SLE: Towards new approaches","volume":"27","author":"van Vollenhoven","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2023041906092671500_R52","article-title":"A phase Ib, open label, multicentre study to investigate the pharmacokinetics, pharmacodynamics, and safety of tocilizumab following subcutaneous administration in patients with polyarticular-course juvenile idiopathic arthritis"},{"key":"2023041906092671500_R53","article-title":"A phase Ib, open label, multicentre study to investigate the pharmacokinetics, pharmacodynamics, and safety of tocilizumab following subcutaneous administration in patients with systemic juvenile idiopathic arthritis"},{"key":"2023041906092671500_R54","article-title":"A Phase 3 multi-center, open-label study to evaluate pharmacokinetics, efficacy and safety of abatacept administered subcutaneously (SC) in children and adolescents with active polyarticular juvenile idiopathic arthritis (pJIA) and inadequate response (IR) to biologic or non biologic disease modifying anti-rheumatic drugs (DMARDs)"},{"key":"2023041906092671500_R55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11926-013-0338-y","article-title":"Tocilizumab in pediatric rheumatology: the clinical experience","volume":"15","author":"Gurion","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2023041906092671500_R56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/BOR.0b013e32835fd828","article-title":"Small molecular compounds in development for rheumatoid arthritis","volume":"25","author":"van Vollenhoven","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"2023041906092671500_R57","article-title":"Refusal of the marketing authorisation for Xeljanz (tofacitinib)","author":"European Medicines Agency","year":"2013"},{"key":"2023041906092671500_R58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/09273948.2013.791701","article-title":"Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors","volume":"21","author":"Heiligenhaus","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"2023041906092671500_R59","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/kes212","article-title":"Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease\u2014a case cohort interventional study","volume":"51","author":"Sen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2023041906092671500_R60","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/ard.2006.065441","article-title":"Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease","volume":"66","author":"Sharma","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023041906092671500_R61","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2023041906092671500_R62","article-title":"Randomised controlled trial of the clinical effectiveness, SafetY and Cost effectiveness of Adalimumab in combination with MethOtRExate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)"},{"key":"2023041906092671500_R63","article-title":"A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus erythematosus (SLE)"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/90\/1068\/590\/50003726\/postgradmedj-90-590.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/90\/1068\/590\/50003726\/postgradmedj-90-590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T06:12:47Z","timestamp":1681884767000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/90\/1068\/590\/6992153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,17]]},"references-count":63,"journal-issue":{"issue":"1068","published-online":{"date-parts":[[2014,9,17]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2013-304396rep","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,10]]},"published":{"date-parts":[[2014,9,17]]}}}